 Aethlon Medical, Inc. Nasdaq: AEMD, a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received European Patent No. 1,993,600 the 600 Patent entitled Extracorporeal Removal of Microvesicular Particles. The 600 patent embodies Aethlons Hemopurifier technology designed for the depletion of immune suppressive, and potentially cancer-promoting, exosomes from the circulatory system. 